Margaret von Mehren, MD, Fox Chase Cancer Center, Philadelphia, PA, talks on the latest research avenues being explored in sarcoma. One major theme is the use of immunotherapy in sarcoma, including CAR-T cell therapy. While evidence collected to date has shown immune-targeting agents to be less effective in sarcoma than other solid tumors, many questions remain about how to optimize their use. Several investigations are underway to establish when to use these agents and predict who is most likely to respond. Dr von Mehren also notes targeted therapies as an important ongoing research theme. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Margaret von Mehren, MD has received research funding from Novartis.